SCHEMBL6441085

SCHEMBL6441085

N#Cc1c(OCCCCc2ccccc2)nc(N)nc1-c1ccco1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 16/20 0.58
ADORA1 P30542 11/20 0.58
ADORA2B P29275 4/20 0.58
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
HSD17B10 Q99714 1/20 0.43
NPSR1 Q6W5P4 1/20 0.41
ADORA3 P0DMS8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5036930 0.97 ADORA2A (0.59) ADORA2AADORA1ADORA2BKDM4EHPGD
SCHEMBL5037058 0.94 ADORA2A (0.60) ADORA2AADORA1ADORA2BKDM4EHPGD
SCHEMBL5046632 0.87 ADORA2A (0.62) ADORA2AADORA1ADORA2BKDM4EHPGD
SCHEMBL6441743 0.84 ADORA1 (0.56) ADORA2AADORA1ADORA2BKDM4EHPGD
SCHEMBL7395254 0.82 ADORA2A (0.52) ADORA2AADORA1ADORA2BKDM4EHPGD
SCHEMBL6440638 0.82 ADORA2A (0.56) ADORA2AADORA1ADORA2BKDM4EHPGD
SCHEMBL5036966 0.82 ADORA2A (0.57) ADORA2AADORA1ADORA2BKDM4EHPGD
SCHEMBL5040411 0.82 ADORA2A (0.54) ADORA2AADORA1ADORA2BKDM4EHPGD
SCHEMBL7889106 0.82 ADORA2A (0.57) ADORA2AADORA1ADORA2BKDM4EHPGD
SCHEMBL5046570 0.81 ADORA1 (0.58) ADORA2AADORA1ADORA2BKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.